

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO. 3589-54 APPLICANT	SERIAL NO. Unassigned	
(Use several sheets if necessary)		HENLEY ET AL. FILING DATE December 1, 2003	GROUP Unassigned	
U.S. PATENT DOCUMENTS				
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS    SUBCLASS    FILING DATE IF APPROPRIATE
CTN	279,524	06/1883	BEATY	607    145
	484,522	10/1892	McBRIDE	
	600,290	03/1898	MUIR	
	1,967,927	07/1934	DEUSTCH	604    20
	2,047,308	07/1936	CHAPMAN	128    799
	2,126,070	08/1938	WAPPLER	
	2,834,344	05/1958	KANAI	
	3,019,787	02/1962	SIMMONS	
	3,048,170	08/1962	LEMOS	
	3,107,672	10/1963	HOFMANN	
	3,163,166	12/1964	BRANT ET AL.	
	3,298,368	01/1967	CHAROS	128    260
	3,520,297	07/1970	BECHTOLD	
	3,645,260	02/1972	CINOTTI ET AL.	
	3,716,054	02/1973	PORTER ET AL.	
	3,831,598	08/1974	TICE	
	3,848,600	11/1974	PATRICK, JR. ET AL.	128    783
	4,116,238	09/1978	PETTIJOHN	128    172.1
	4,211,222	07/1980	TAPPER	128    803
	4,292,968	10/1981	ELLIS	128    207.21
	4,301,794	11/1981	TAPPER	604    20
	4,325,367	04/1982	TAPPER	
	4,383,529	05/1983	WEBSTER	
	4,393,884	07/1983	JACOBS	131    273
	4,406,658	09/1983	LATTIN ET AL.	604    20
	4,416,274	11/1983	JACOBSEN ET AL.	128    803
	4,429,703	02/1984	HABER	131    273
	4,474,570	10/1984	ARIURA ET AL.	604    20
	4,510,939	04/1985	BRENMAN ET AL.	128    639
	4,639,244	01/1987	RIZK ET AL.	
	4,655,229	04/1987	SENSABAUGH, JR. ET AL.	131    273
	4,665,921	05/1987	TERANISHI ET AL.	
	4,689,039	08/1987	MASAKI	
	4,702,732	10/1987	POWERS ET AL.	
	4,708,716	11/1987	SIBALIS	604    20
	4,735,217	04/1988	GERTH ET AL.	131    273
▼	4,747,819	05/1988	PHIPPS ET AL.	

\*Examiner CTN *group* Date Considered 1/11/06

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO. 3589-54	SERIAL NO. Unassigned			
		APPLICANT HENLEY ET AL.				
(Use several sheets if necessary)		FILING DATE December 1, 2003	GROUP Unassigned			
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CTN	4,756,318	07/1988	CLEARMAN ET AL.	131	359	
	4,763,660	08/1988	KROLL ET AL.	128	798	
	4,764,164	08/1988	SASAKI	604	20	
	4,767,402	08/1988	KOST ET AL.			
	4,771,796	09/1988	MYER	131	273	
	4,776,353	10/1988	LILJA ET AL.	131	297	
	4,786,278	11/1988	MASAKI	604	20	
	4,787,888	11/1988	FOX			
	4,793,366	12/1988	HILL	131	273	
	4,800,903	01/1989	RAY ET AL.	131	273	
	4,808,152	02/1989	SIBALIS	604	20	
	4,813,437	03/1989	RAY	131	273	
	4,820,263	04/1989	SPEVAK ET AL.	604	20	
	4,821,740	04/1989	TACHIBANA ET AL.	604	20	
	4,838,273	06/1989	CARTMELL	600	392	
	4,865,582	09/1989	SIBALIS	604	20	
	4,907,606	03/1990	LILJA ET AL.	131	273	
	4,913,148	04/1990	DIETHELM			
	4,917,119	04/1990	POTTER ET AL.	131	273	
	4,919,648	04/1990	SIBALIS	604	20	
	4,922,901	05/1990	BROOKS ET AL.	128	203.26	
	4,931,046	06/1990	NEWMAN	604	20	
	4,942,883	07/1990	NEWMAN	604	20	
	4,950,229	08/1990	SAGE, JR.	604	20	
	4,953,565	09/1990	TACHIBANA ET AL.	604	20	
	4,957,480	09/1990	MORENINGS			
	4,979,938	12/1990	STEPHEN ET AL.			
	4,997,418	03/1991	DeMARTINI			
	5,002,527	03/1991	RELLER ET AL.			
	5,006,108	04/1991	LaPRADE	604	20	
	5,019,034	05/1991	WEAVER ET AL.	604	20	
	5,037,381	08/1991	BOCK ET AL.			
	5,042,975	08/1991	CHIEN ET AL.			
	5,047,007	09/1991	McNICHOLS ET AL.	604	20	
	5,053,001	10/1991	RELLER ET AL.	604	20	
	5,060,671	10/1991	COUNTS ET AL.	131	329	

\*Examiner

CT Nguyen

Date Considered

1/9/06

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO. 3589-54	SERIAL NO. Unassigned			
		APPLICANT HENLEY ET AL.				
(Use several sheets if necessary)		FILING DATE December 1, 2003	GROUP Unassigned			
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CTN	5,090,402	02/1992	BAZIN ET AL.			
	5,115,805	05/1992	BOMMANNAN ET AL.			
	5,133,352	07/1992	LATHROP ET AL.			
	5,135,478	08/1992	SIBALIS			
	5,135,479	08/1992	SIBALIS ET AL.	604	20	
	5,147,291	09/1992	CUKIER	604	22	
	5,160,316	11/1992	HENLEY	604	20	
	5,162,042	11/1992	GYORY ET AL.			
	5,167,242	12/1992	TURNER ET AL.	131	273	
	5,169,384	12/1992	BOSNIAK ET AL.			
	5,171,215	12/1992	FLANAGAN	604	20	
	5,203,768	04/1993	HAAK ET AL.			
	5,250,022	10/1993	CHIEN ET AL.			
	5,254,081	10/1993	MAURER ET AL.	604	20	
	5,279,543	01/1994	GLIKFELD ET AL.			
	5,284,471	02/1994	SAGE, JR.			
	5,298,017	03/1994	THEEUWES ET AL.			
	5,310,404	05/1994	GYORY ET AL.			
	5,312,326	05/1994	MYERS ET AL.			
	5,314,502	05/1994	MCNICHOLS ET AL.			
	5,331,979	07/1994	HENLEY			
	5,354,321	10/1994	BERGER			
	5,360,440	11/1994	ANDERSEN			
	5,362,307	11/1994	GUY ET AL.			
	5,362,308	11/1994	CHIEN ET AL.			
	5,374,241	12/1994	LLOYD ET AL.			
	5,374,242	12/1994	HAAK ET AL.			
	5,376,107	12/1994	INAGI ET AL.			
	5,391,195	02/1995	VAN GRONINGEN			
	5,395,310	03/1995	UNTEREKER ET AL.			
	5,413,590	05/1995	WILLIAMSON			
	5,415,629	05/1995	HENLEY			
	5,421,816	06/1995	LIPKOVKER			
	5,441,936	08/1995	HOUGHTEN ET AL.			
	5,443,441	08/1995	De CLAVIERE			
▼	5,458,569	10/1995	KIRK III ET AL.	604	20	
*Examiner	CTNnguyen	Date Considered	1/9/06			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO. 3589-54	SERIAL NO. Unassigned			
		APPLICANT HENLEY ET AL.				
(Use several sheets if necessary)		FILING DATE December 1, 2003	GROUP Unassigned			
<b>U.S. PATENT DOCUMENTS</b>						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CTN	5,464,387	11/1995	HAAK ET AL.			
	5,466,217	11/1995	MYERS ET AL.			
	5,470,349	11/1995	KLEDITSCH ET AL.			
	5,494,679	02/1996	SAGE, JR. ET AL.			
	5,501,705	03/1996	FAKHRI			
	5,514,167	05/1996	SMITH ET AL.			
	5,538,503	07/1996	HENLEY			
	5,540,669	07/1996	SAGE, JR. ET AL.	604	20	
	5,551,953	09/1996	LATTIN ET AL.			
	5,558,632	09/1996	LLOYD ET AL.			
	5,562,607	10/1996	GYORY			
	5,589,563	12/1996	WARD ET AL.			
	5,603,693	02/1997	FRENKEL ET AL.			
	5,607,461	03/1997	LATHROP			
	5,607,691	03/1997	HALE ET AL.			
	5,618,275	04/1997	BOCK			
	5,658,247	08/1997	HENLEY			
	5,667,487	09/1997	HENLEY			
	5,668,170	09/1997	GYORY			
	5,676,648	10/1997	HENLEY			
	5,678,273	10/1997	PORCELLI			
	5,688,233	11/1997	HOFMANN ET AL.			
	5,697,896	12/1997	McNICHOLS ET AL.			
	5,700,457	12/1997	DIXON			
	5,711,761	01/1998	UNTEREKER ET AL.			
	5,713,846	02/1998	BERNHARD ET AL.			
	5,722,397	03/1998	EPPSTEIN			
	5,725,817	03/1998	MILDER			
	5,733,255	03/1998	DINH ET AL.			
	5,755,750	05/1998	PETRUSKA ET AL.			
	5,788,666	08/1998	ATANASOSKA			
	5,794,774	08/1998	PORCELLI			
	5,795,321	08/1998	MCARTHUR ET AL.			
	5,797,867	08/1998	GUERRARA ET AL.			
	5,830,175	11/1998	FLOWER			
	5,840,057	11/1998	ALOISI			

\*Examiner CTN guyen Date Considered 1/9/06

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.			
CITATION		3589-54	Unassigned			
APPLICANT						
HENLEY ET AL.						
(Use several sheets if necessary)		FILING DATE	GROUP			
		December 1, 2003	Unassigned			
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CTN	5,846,217	12/1998	BECK ET AL.			
	5,865,786	02/1999	SIBALIS ET AL.	604	20	
	5,879,323	03/1999	HENLEY			
	5,882,676	03/1999	LEE ET AL.			
	5,899,875	5/1999	MILLOT			
	5,899,876	05/1999	FLOWER	604	20	
	5,908,401	06/1999	HENLEY	604	20	
	5,911,319	06/1999	PORCELLI ET AL.			
	5,919,155	07/1999	LATTIN ET AL.	604	20	
	5,931,859	08/1999	BURKE			
	5,935,598	08/1999	SAGE ET AL.			
	5,954,684	09/1999	FLOWER ET AL.	604	20	
	5,961,482	10/1999	CHIEN ET AL.			
	5,961,483	10/1999	SAGE ET AL.			
	5,968,005	10/1999	TU			
	5,968,006	10/1999	HOFMANN			
	5,983,130	11/1999	PHIPPS ET AL.			
	6,004,309	12/1999	PHIPPS			
	6,004,547	12/1999	ROWE ET AL.			
	6,006,130	12/1999	HIGO ET AL.			
	6,018,679	01/2000	DINH ET AL.			
	6,023,639	02/2000	HAKKY ET AL.			
	6,032,073	02/2000	EFFENHAUSER			
	6,038,485	03/2000	AXELGAARD			
	6,041,252	03/2000	WALKER ET AL.			
	6,041,253	03/2000	KOST ET AL.			
	6,048,545	04/2000	KELLER ET AL.			
	6,057,374	05/2000	HUNTINGTON ET AL.			
	6,101,411	08/2000	NEWSOME			
	6,148,231	11/2000	HENLEY	604	20	
	6,148,232	11/2000	AVRAHAMI	604	20	
	6,167,302	12/2000	MILLOT			
	6,385,487 B1	05/2002	HENLEY	604	20	
	3,556,105	1/1971	SHEPARD			

\*Examiner CTN Nguyen Date Considered 1/9/04

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

3589-54

SERIAL NO.

Unassigned

APPLICANT

HENLEY ET AL.

(Use several sheets if necessary)

FILING DATE

GROUP

December 1, 2003

Unassigned

**FOREIGN PATENT DOCUMENTS**

TRANSLATION

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
CTN OE 0,232,642	03/1964	AT	604	20		
EP 617979 A1	10/1994	EPO				
FR 1,445,703	06/1966	FR	604	20		
FR 2 513 129	03/1983	FR				
GB 0,299,553	11/1928	GB	604	20		
EP 0230749	08/1987	EPO	604	20		
EP 0309093 A1	03/1989	EPO	604	20		
3-170172	07/1991	JP			X	
WO 90/06153	06/1990	PCT			X	
SU654254	03/1979	U.S.S.R.			X	
SU931191	05/1982	U.S.S.R.			X	
SU1003853	03/1983	U.S.S.R.			X	
08571	08/1990	WIPO	604	20	X	
03790	03/1993	WIPO	604	20		
07269	12/1986	WIPO	604	20		

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

CTN	"Iontophoretic Treatment of Oral Herpes," Henley et al.; Laryngoscope, Vol. 94, No. 1, pp. 118-121, January 1984
	"Iontophoretic Application of Idoxuridine for Recurrent Herpes Labialis: Report of Preliminary Chemical Trials," Gangarosa et al.; Meth. And Find. Exptl. Clin. Pharmacol. 1(2), pp. 105-109 (1979)
	"Iontophoresis of Vidarabine Monophosphate for Herpes Orolabialis," Gangarosa et al.; The Journal of Infectious Diseases, Vol. 154, No. 6, pp. 930-934, December 1986
	"The Natural History of Recurrent Herpes Simplex Labialis," Spruance et al.; The New England Journal of Medicine, Vol. 297, No. 2, pp. 69-75, July 14, 1977
	"Infection with Herpes-Simplex Viruses 1 and 2," Nahmias et al.; The New England Journal of Medicine, pp. 667-674, September 27, 1973
	"Anesthesia of the Human Tympanic Membrane by Iontophoresis of a Local Anesthetic," Comeau et al.; The Laryngoscope, 88:1978, pp. 277-285
	"Iontophoretic Application of Drugs," Waud, J. Appl. Physiol. 23(1), 1967, pp. 128-130
	"Antibiotic Iontophoresis in the Treatment of Ear Chondritis," LaForest et al., Physical Therapy, Vol. 58, No. 1, January 1978, pp. 32-34
	"The Quantity and Distribution of Radiolabeled Dexamethasone Delivered to Tissue by Iontophoresis," Glass et al.; International Journal of Dermatology, Vol. 19, November 1980, pp. 519-525
	"Iontophoretic Application of Antiviral Chemotherapeutic Agents," Hill et al., Annals New York Academy of Sciences, pp. 604-612
↓	"Ocular Iontophoresis," Hill et al. Paper, Louisiana State University Medical Center, School of Medicine, New Orleans, Louisiana, pp. 331-354

\*Examiner

CTN Nguyen

Date Considered

CT Nguyen

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.
CITATION		3589-54	Unassigned
APPLICANT			
HENLEY ET AL.			
(Use several sheets if necessary)		FILING DATE	GROUP
		December 1, 2003	Unassigned

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, etc.)**

CTN	<p>"Iontophoretic Application of Adenine Arabinoside Monophosphate to Herpes Simplex Virus Type 1-Infected Hairless Mouse Skin," Park et al.; Antimicrobial Agents and Chemotherapy, Vol. 14, No. 4, Oct., 1978, pp. 605-608</p> <p>"Iontophoresis: Applications in Transdermal Medication Delivery," Costello et al.; Physical Therapy, Vol. 75, No. 6, pp. 104/554-113/563, June 1995</p> <p>"Physical Enhancement of Dermatologic Drug Delivery: Iontophoresis and Phonophoresis, Kassan et al., Journal of the American Academy of Dermatology, April 1996, pp. 657-666</p> <p>"Iontophoresis and Herpes Labialis," Boxhall et al.; The Medical Journal of Australia, May 26, 1984, pp. 686-687</p> <p>"Iontophoresis: A Method of Antibiotic Administration in the Burn Patient," Rapperport et al., Plastic and Reconstructive Surgery, 1965, Vol. 36, No. 5, pp. 547-552</p> <p>"Iontophoresis for Enhancing Penetration of Dermatologic and Antiviral Drugs," Gangarosa et al., Journal of Dermatology, Vol. 22, No. 11, pp. 865-875, November 1995</p> <p>"Iontophoretic Treatment of Herpetic Whitlow," Gangarosa et al., Arch. Phys. Med. Rehabil., Vol. 70, pp. 336-340 April 1989</p> <p>"Iontophoretic Application of Antiviral Drugs," Gangarosa et al., Proceedings of an International Symposium held in Tokushima City, Japan, pp. 201-204, July 27-30, 1981</p> <p>"Iontophoretic Application of Adenine Arabinoside Monophosphate for the Treatment of Herpes Simplex Virus Type 2 Skin Infections in Hairless Mice," Gangarosa, The Journal of Infectious Diseases, Vol. 140, No. 6, pp. 1014, December 1979</p> <p>"Effect of Iontophoretic and Topical Application of Antiviral Agents in Treatment of Experimental HSV-1 Keratitis in Rabbits," Kwon et al., Investigative Ophthalmology &amp; Visual Science, Vol. 18, No. 9, pp. 984-988, September, 1979</p> <p>"Acyclovir and Vidarabine Monophosphate: Comparison of Iontophoretic and Intravenous Administration for the Treatment of HSV-1 Stromal Keratitis," Hill et al., The American Journal of Medicine, Acyclovir Symposium, pp. 300-304</p> <p>"Thymine Arabinoside (Ara-T) Topical and Iontophoretic Applications for Herpes Simplex Virus Type 1 and Type 2 Skin Infections in Hairless Mice," Hill et al., Meth. And Find. Exptl. Clin. Pharmacol. 6(1), pp. 17-20, 1984</p> <p>"Iontophoresis Enhances the Transport of Acyclovir Through Nude Mouse Skin by Electrorepulsion and Electroosmosis," Volpatto et al., Pharmaceutical Research, Vol. 12, No. 11, pp. 1623-1627, 1995</p> <p>"Early Application of Topical 15% Idoxuridine n Dimethyl Sulfoxide Shortens the Course of Herpes Simplex Labialis: A Multicenter Placebo-Controlled Trial," Spruance et al., The Journal of Infectious Diseases, 1990; Vol. 161; pp. 191-197</p> <p>"Iontophoresis for Surface Local Anesthesia," Gangarosa, JADA, Vol. 88, pp. 125-128, January 1974</p> <p>"Conductivity of Drugs Used for Iontophoresis," Gangarosa et al., Journal of Pharmaceutical Sciences, Vol. 67, No. 10, pp. 1439-1443, October, 1978</p> <p>"A Pilot Study of Iontophoretic Cisplatin Chemotherapy of Basal and Squamous Cell Carcinomas of the Skin," Chang et al., Arch. Dermatol., Vol. 129, pp. 425-427, April 1993</p> <p>"How Modern Iontophoresis Can Improve Your Practice," Gangarosa et al., (Quintessence International) Oral Surgery, No. 10, Report 2135, October 1982, pp. 1027-1038</p> <p>"Postherpetic Neuralgia," Baron et al., Brain (1993), 116, pp. 1477-1496</p>		
*Examiner	C T Nguyen	Date Considered	1/9/06

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO. <b>3589-54</b>	SERIAL NO. <b>Unassigned</b>
		APPLICANT <b>HENLEY ET AL.</b>	
(Use several sheets if necessary)		FILED DATE <b>December 1, 2003</b>	GROUP <b>Unassigned</b>
<b>OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)</b>			
CTN		<p>"Iontophoretic Assistance of 5-Iodo-2'-Deoxyuridine Penetration into Neonatal Mouse Skin and Effects of DNA Synthesis," Gangarosa et al., Society for Experimental Biology and Medicine, pp. 439-443, 1977</p> <p>"Electrophoretic Evaluation of the Mobility of Drugs Suitable for Iontophoresis," Kamath et al., Meth. Find. Exp. Clin. Pharmacol., 1995, 17(4): pp. 227-232</p> <p>"Transdermal Drug Delivery by Passive Diffusion and Iontophoresis: A Review," Singh et al., Medicinal Research Reviews, Vol. 13, No. 5, 1993, pp. 569-621</p> <p>"Iontophoresis: Electorepulsion and Electroosmosis," Guy et al., Journal of Controlled Release 64 (2000) 129-132</p> <p>"Treatment of Common Cutaneous Herpes Simplex Virus Infections," Emmert, American Family Physician, Vol. 61, No. 6, March 15, 2000, pp. 1697-1704</p> <p>"Gelatini-stabilised Microemulsion-Based Oranogels: Rheology and Application in Iontophoretic Transdermal Drug Delivery," Kantaria et al., Journal of Controlled Release 60 (1999) 355-365</p> <p>"Electrorepulsion Versus Electroosmosis: Effect of pH on the Iontophoretic Flux of 5-Fluorouracil," Merino et al., Pharmaceutical Research, Vol. 16, No. 6 (1999)</p> <p>"Azelaic Acid: Potential as a General Antitumoural Agent," Breathnach, Medical Hypotheses (1999) 52(3) 221-226</p> <p>"Treatment of Mucocutaneous Herpes Simplex Virus Infections Unresponsive to Acyclovir with Topical Foscarnet Cream in AIDS Patients: A Phase I/II Study," Javaly et al., Journal of Acquired Immune Deficiency Syndromes 21:301-306</p> <p>"Efficacy and Safety of Azelaic Acid and Glycolic Acid Combination Therapy Compared with Tretinoin Therapy for Acne," Spellman et al., Clinical Therapeutics, Vol. 20, No. 4, 1998, pp. 711-721</p> <p>"Passive Versus Electrotransport-Facilitated Transdermal Absorption of Ketorolac," Park et al., Clinical Pharmacology &amp; Therapeutics, Vol. 63, No. 3, pp. 303-315</p> <p>"Soriudine Versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial," Gnann et al., Antimicrobial Agents and Chemotherapy, Vol. 42, No. 5, May 1998, pp. 1139-1145</p> <p>"Azelaic Acid 20% Cream (AZELEX®) and the Medical Management of Acne Vulgaris," Gibson, Dermatology Nursing, Vol. 9, No. 5, pp. 339-344</p> <p>"Sorivudine: A Promising Drug for the Treatment of Varicella-Zoster Virus Infection," Whitley, Neurology 1995; 45 (Supp. 8), pp. S73-S75</p> <p>"Antiherpesviral and Anticellular Effects of 1-<math>\beta</math>-D-Arabinofuranosyl-E-5-(2-Halogenovinyl) Uracils," Machida et al., Antimicrobial Agents and Chemotherapy, July 1981, pp. 47-52</p> <p>"Herpes Simplex," American Academy of Dermatology, 1987, Revised 1991, 1993</p> <p>"Common Cold' Virus is Near," Haney, The Associated Press, January 15, 2000</p> <p>"New Medicines Move to Eradicate Acne," Hemphill, The New York Times, February 29, 2000</p> <p>"Warts," American Academy of Dermatology, American Academy of Dermatology, 1997, Revised 1991, 1993</p> <p>"Psoriasis," American Academy of Dermatology, 1994</p> <p>"Eczema/Atopic Dermatitis," American Academy of Dermatology, 1987, Revised 1991, 1993, 1995</p> <p>"Skin Cancer: An Undeclared Epidemic," American Academy of Dermatology, 1988, Revised 1989, 1993, 1994</p> <p>"Electrophoretically Controlled Dermal or Transdermal Application Systems with Electronic Indicators," Gröning, International Journal of Pharmaceutics, 36 (1987) pp. 37-40</p>	
*Examiner	<i>CT Nguyen</i>	Date Considered	<i>1/9/04</i>

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Atty. Docket N .	Serial N .
3589-54	Unassigned
Applicant	
HENLEY ET AL.	
Filing Date	Group
December 1, 2003	Unassigned

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

## **TRANSLATION**

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

*Examiner	CT Nguyen	Date Considered	1/9/06
-----------	-----------	-----------------	--------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.